Oncology

Obese Individuals May Have Greater Metastatic Melanoma Survival Odds

February 21, 2018

The obesity-related survival benefit was seen only for patients receiving targeted therapy (hazard ratios, 0.72 and 0.6 for progression-free and overall survival, respectively) and immunotherapy (hazard ratios, 0.75 and 0.64, respectively), not for patients receiving chemotherapy.

Imfinzi Approved to Treat Stage III Non-Small Cell Lung Cancer

By February 20, 2018

The approval of Imfinzi is based on the positive PFS data from the Phase 3 PACIFIC trial.

Parental Awareness Lacking for Dangers of Indoor Tanning

February 20, 2018

Parent sex, parent indoor tanning use, and adolescents' skin reactivity were associated with perceiving high indoor tanning benefits.

FDA-Approved Prostate Cancer Treatments

February 20, 2018

Approved prostate cancer drug treatments including formulations and usual dosing.

Many Young Cancer Survivors Not Receiving Follow-Up Care

February 16, 2018

Since 2015, 37% had no follow-up visit, with no significant variation seen across disease types. Overall, 33 and 48% of cohorts A and B, respectively, were not seen in 2016, regardless of insurance coverage.

Induced Pluripotent Stem Cells Show Promise in Preventing Tumor Growth

February 16, 2018

The iPSC vaccine inhibited melanoma recurrence at the resection site as an adjuvant and reduced metastatic tumor load, which was correlated with fewer Th17 cells and increased CD11b+GR1hi myeloid cells.

Erleada Approved for Non-Metastatic, Castration-Resistant Prostate Cancer

By February 15, 2018

Erleada is the first FDA-approved therapy to treat patients with non-metastatic castration-resistant prostate cancer.

How Strong is the Correlation Between Processed Food and Breast CA?

February 15, 2018

The researchers observed a correlation for ultra-processed food intake with increased overall cancer risk (hazard ratio for a 10% increment in the proportion of ultra-processed food in the diet, 1.12) and increased breast cancer risk (hazard ratio, 1.11)

Selumetinib Gets Orphan Drug Designation for Neurofibromatosis Type 1

February 15, 2018

NF1 has no known cure and is associated with highly-variable symptoms

FDA-Approved Non-Small Cell Lung Cancer (NSCLC) Treatments

February 13, 2018

Non-small cell lung cancer (NSCLC) treatment regimen chart.0

FDA-Approved Colorectal Cancer Treatments

February 13, 2018

Colorectal cancer treatment regimen chart.

FDA-Approved Breast Cancer Treatments

February 13, 2018

Treatment chart with usual dosage, strength, and formulation of FDA approved medications for breast cancer.

USPSTF Issues Recommendation Statement on Ovarian Cancer Screening

February 13, 2018

Adequate evidence was also found suggesting that the harms of screening may be substantial in some cases, including unnecessary surgery in women without cancer. Based on these findings, the USPSTF concludes with moderate certainty that the harms of ovarian cancer screening outweigh the potential benefits.

Open-Label Placebo May Benefit QoL in Cancer Survivors

February 12, 2018

The researchers found that participants randomized to open-label placebo reported a 29% improvement in fatigue severity and a 39% improvement in fatigue-disrupted quality of life compared to those randomized to treatment as usual.

Outcomes Assessed for HPV-Related Head, Neck CA Requiring Resections

February 12, 2018

Surgery and adjuvant therapy used for invasive nodal disease requiring extensive neck dissection. Researchers found that regional recurrences were seen in 6% of patients, and 17% experienced distant recurrences.

Prognostic Survival Model Developed for Treatment of Urothelial Cancer

February 09, 2018

"We believe we've developed the first prognostic model that, once confirmed in larger studies, could provide a critical decision-making tool for clinicians," said lead author Gregory Russell Pond, PhD.

Atezolizumab + Bevacizumab vs. Sunitinib in Met Renal CA

February 09, 2018

The researchers found that the hazard ratio for progression-free survival was 0.74 and 0.83 for atezolizimab plus bevacizumab versus sunitinib in PD-L1+ patients and intention-to-treat patients, respectively.

Positive Results Released for Novel Prostate Cancer Tx

February 09, 2018

The researchers found that the median metastasis-free survival was 40.5 months in the apalutamide group and 16.2 months in the placebo group in the planned primary analysis performed after 378 events had occurred. Also significantly longer time to symptomatic progression was seen with apalutamide versus placebo.

Zytiga Approved for Metastatic High-Risk Castration-Sensitive Prostate Cancer

By February 08, 2018

The FDA approval was supported by results from the Phase 3 multinational, multicenter, randomized, double-blind, placebo-controlled LATITUDE trial (N=1,199) which evaluated Zytiga 1000mg once daily in combination with prednisone 5mg once daily vs placebo in newly diagnosed, metastatic high-risk CSPC patients who had not received prior cytotoxic chemotherapy.

Mogamulizumab Evaluated in Patients With HTLV-1-Associated Myelopathy

February 08, 2018

Findings in patients with HTLV-1-associated myelopathy-tropical spastic paraparesis

Does Drinking Hot Tea Increase Esophageal Cancer Risk?

February 06, 2018

Compared with hot tea drinking alone, hot tea drinking combined with either alcohol consumption or smoking was associated with increased risk for esophageal cancer.

NTP: Cell Phone Radiofrequency Energy Exposure Report Released

By February 05, 2018

The level of wattage at incidence was higher than the allowable level for cell phone emissions. Increases were also noted tumor incidences in other organs of rats and mice, including the brain, prostate gland, pituitary gland, adrenal gland, liver, and pancrease.

AHA: Managing Breast CA Patients CVD Risk Requires Comprehensive Care

February 01, 2018

Current treatment for breast cancer can have a negative effect on cardiovascular health such as left ventricular dysfunction and accelerated CVD;

In Situ Vaccine Shows Promise in Using Immune Response to Treat Cancer

February 01, 2018

"This combination of a TLR ligand and an anti-OX40 antibody can cure multiple types of cancer and prevent spontaneous genetically driven cancers," the authors write.

Tisagenlecleucel Tx Examined in Youths With B-Cell Acute Lymphoblastic Leukemia

February 01, 2018

For as long as 20 months, persistence of tisagenlecleucel in the blood was observed. Seventy-three percent of patients had grade 3 or 4 adverse events that were suspected to be related to tisagenlecleucel.

Five-Year Worldwide Net Cancer Survival Rates Examined

January 31, 2018

The researchers found that estimated 5-year net survival remained among the highest in the world in the United States and Canada; Australia and New Zealand; and Finland, Iceland, Norway, and Sweden for most cancers.

Antiemetic Treatments

January 30, 2018

Antiemetic treatment chart including drug formulations, strengths, and usual doses for nausea/vomiting.

How E-Cigarette Smoke May Damage DNA, Inhibit Repair

January 30, 2018

"These results indicate that nicotine nitrosation occurs in vivo in mice and that e-cigarette smoke is carcinogenic to the murine lung and bladder and harmful to the murine heart," the authors write.

MRI Diagnostic for Differentiating Low-Grade Bladder Cancers

January 29, 2018

Across studies, the pooled sensitivity of MR imaging was 0.90 and the specificity was 0.88 for differentiating tumors staged T1 or lower from those staged T2 or higher.

Lutathera Approved for Gastroenteropancreatic Neuroendocrine Tumors

By January 26, 2018

Lutathera is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.